Can an 8-year-old pediatric patient take a 10 mg dose of montelukast (Singulair)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 24, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can an 8-Year-Old Take 10 mg Montelukast?

No, an 8-year-old should NOT take 10 mg montelukast—the correct dose is 5 mg chewable tablet once daily.

FDA-Approved Dosing by Age

The FDA drug label for montelukast (Singulair) provides clear age-based dosing 1:

  • Ages 6-14 years: 5 mg chewable tablet once daily
  • Ages 15 years and older: 10 mg tablet once daily
  • Ages 2-5 years: 4 mg chewable tablet or oral granules
  • Ages 12-23 months: 4 mg oral granules

Since your patient is 8 years old, they fall squarely in the 6-14 year age group and should receive 5 mg, not 10 mg.

Why This Dosing Matters

The pediatric dose selection was based on pharmacokinetic studies demonstrating that a 5 mg chewable tablet in children aged 6-14 years provides comparable systemic drug exposure (area under the plasma concentration-time curve) to the adult 10 mg dose 2, 3. This means the 5 mg dose already delivers equivalent therapeutic effect in this age group—giving 10 mg would result in excessive drug exposure without additional benefit.

Clinical Context from Guidelines

Multiple NAEPP guidelines confirm montelukast is approved for children older than 1 year, with leukotriene receptor antagonists serving as appropriate alternative therapies for mild persistent asthma when inhaled corticosteroids cannot be used 4. The guidelines consistently reference age-appropriate dosing, with the 5 mg dose specifically designated for the 6-14 year age range 5, 6.

Important Safety Considerations

The FDA issued a Boxed Warning for montelukast in March 2020 regarding serious neuropsychiatric events including agitation, depression, sleep disturbances, suicidal thoughts, and behavioral changes 7, 1. While a recent 2025 Swedish study found no increased risk compared to LABAs 8, and a 2022 pediatric study reported ADRs in 31.9% of children (predominantly sleep disturbance 15.1%, agitation 10.4%) with no serious events 9, the warning remains in effect.

Reserve montelukast use for patients with inadequate response or intolerance to alternative therapies, particularly for allergic rhinitis 1. For asthma, inhaled corticosteroids remain the preferred first-line controller medication in children 10, 11.

Bottom Line

Prescribe 5 mg chewable tablet once daily for this 8-year-old patient. The 10 mg dose is inappropriate for this age group and would provide excessive drug exposure. Counsel the family about potential neuropsychiatric side effects and ensure they understand this is a controller medication, not a rescue inhaler.

References

Research

Adverse Drug Reactions (ADRs) of Montelukast in Children.

Children (Basel, Switzerland), 2022

Research

Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.